Tr1X is developing a novel class of regulatory T cell-based (Treg) products to cure autoimmune and inflammatory disorders and transform patient lives.
Company Overview
Our novel regulatory T cell-based therapeutics are designed to mimic the function of naturally occurring T regulatory type 1 regulatory T (Tr1) cells, a lesser known subset of Tregs. Our products work to restore tolerance, stopping severe autoimmune and inflammatory diseases in their tracks.
The Science
Our Platform
We are combining the latest advances in genetic engineering with decades of T cell biology research to develop scalable, effective cellular therapies targeting inflammation and autoimmunity
01
Our cells produce plenty of suppressive cytokines in local microenvironments, while preserving desired immune responses.
.svg)
02
Our cells are stable and long lived, even in inflammatory environments.
.svg)
03
Our cells migrate to sites of inflammation, tolerizing cells and inducing de-novo Tr1 cells.
Team
We are pursuing breakthrough innovation in the spaces of autoimmunity and inflammation with a world-class team aiming to change the way devastating diseases are treated.
Our Team
Careers
We strive to create a collaborative, diverse environment to bring the best out of one another. We are committed to our goals, and to one another, while making sure we enjoy the journey as much as the destination.
View Open Positions
